- Home
- ATLC vs BBNX Comparison
ATLC vs BBNX Comparison
Compare ATLC & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLC
- BBNX
- Stock Information
- Founded
- ATLC 1996
- BBNX 2015
- Country
- ATLC United States
- BBNX United States
- Employees
- ATLC N/A
- BBNX N/A
- Industry
- ATLC Finance: Consumer Services
- BBNX Medical/Dental Instruments
- Sector
- ATLC Finance
- BBNX Health Care
- Exchange
- ATLC Nasdaq
- BBNX Nasdaq
- Market Cap
- ATLC 900.3M
- BBNX 740.7M
- IPO Year
- ATLC 1999
- BBNX 2025
- Fundamental
- Price
- ATLC $72.60
- BBNX $23.29
- Analyst Decision
- ATLC Buy
- BBNX Strong Buy
- Analyst Count
- ATLC 7
- BBNX 10
- Target Price
- ATLC $76.29
- BBNX $24.40
- AVG Volume (30 Days)
- ATLC 44.2K
- BBNX 700.7K
- Earning Date
- ATLC 11-06-2025
- BBNX 11-06-2025
- Dividend Yield
- ATLC N/A
- BBNX N/A
- EPS Growth
- ATLC 35.13
- BBNX N/A
- EPS
- ATLC 5.69
- BBNX N/A
- Revenue
- ATLC $457,158,000.00
- BBNX $69,830,000.00
- Revenue This Year
- ATLC $293.56
- BBNX $42.80
- Revenue Next Year
- ATLC $12.64
- BBNX $34.58
- P/E Ratio
- ATLC $12.79
- BBNX N/A
- Revenue Growth
- ATLC 26.20
- BBNX 38911.17
- 52 Week Low
- ATLC $31.10
- BBNX $8.89
- 52 Week High
- ATLC $78.91
- BBNX $26.66
- Technical
- Relative Strength Index (RSI)
- ATLC 68.07
- BBNX 54.39
- Support Level
- ATLC $66.55
- BBNX N/A
- Resistance Level
- ATLC $78.91
- BBNX $26.66
- Average True Range (ATR)
- ATLC 2.51
- BBNX 1.36
- MACD
- ATLC 0.30
- BBNX -0.53
- Stochastic Oscillator
- ATLC 55.44
- BBNX 87.36
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.